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SUMMARY
The ‘Zomig Appropriate for Primary care’ programme
was developed to address the needs of primary care physi-
cians (PCPs) to improve migraine management. As part
of the programme, an international, open-label, 6-month
clinical study was performed. The study included new
and tangible outcome variables relevant to PCPs and
recruited patients presenting in primary care with an
established migraine diagnosis. Patients treated up to
three migraine attacks per month with zolmitriptan orally
disintegrating tablet (ODT) 2.5 mg. All other migraine
attacks occurring during the study period were treated
with the patient’s usual migraine medication (including
other triptans). Questionnaires were used to record
patient treatment experiences at the study end. The pri-
mary end-point was the proportion of patients wanting
to continue using zolmitriptan ODT. Some 595 patients
treated 7171 migraine attacks with zolmitriptan ODT.
Of the 504 patients who completed the 6-month ques-
tionnaire, 380 (75.4%) wished to continue using zolmi-
triptan ODT. The results of the study indicate that
patient-orientated end-points are more motivational and
meaningful to physicians than traditional end-points used
in controlled clinical trials, allowing them to make
informed decisions regarding migraine management.
Keywords: Migraine; primary care; zolmitriptan orally
disintegrating tablet; Zomig Appropriate for Primary care
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INTRODUCTION
Primary care physicians (PCPs) are the only point of contact
for the majority of patients suffering from migraine attacks,
as only a small proportion of these patients are referred to a
neurologist or headache specialist. However, PCPs receive lit-
tle formal education regarding migraine, and management
guidelines are generally impractical for use in routine clinical
practice. Consequently, migraine- and headache-related
knowledge tends to be variable among PCPs (1,2), and many
migraine sufferers who consult PCPs for migraine do not
receive a correct diagnosis. A study from the USA showed
that more than half of patients with migraine, as deﬁned by
the International Headache Society (IHS) criteria (3), were
incorrectly diagnosed by a physician (4).
Of those patients correctly diagnosed as suffering from
migraine, many are inadequately treated. Indeed, a high
proportion of PCPs prescribe simple analgesics and non-ste-
roidal anti-inﬂammatory drugs (NSAIDs) for migraine
(even for severe attacks), rather than migraine-speciﬁc treat-
ments (2,5). Follow up is frequently poor, and many
patients lapse from care (6). This is reﬂected in the high
proportion of patients taking over-the-counter pain medica-
tion, resulting in a high incidence of dissatisfaction among
patients (7). For the majority of patients, however, migraine
is generally treatable.
The 5-HT1B/1D receptor agonists, known as the triptans,
are migraine-speciﬁc agents that have revolutionised the
treatment of migraine. Although triptans are proven to be
effective and well tolerated in the acute treatment of
migraine attacks (8), research indicates that there is an
under-utilisation of these agents in primary care (9). To bet-
ter understand the patient beneﬁts of prescribing triptans,
therefore, PCPs require information on more patient-rele-
vant end-points than those typically used in most clinical
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controlled clinical studies (e.g. 2-h headache response, typic-
ally deﬁned as an improvement in pain intensity from mod-
erate to severe at baseline to mild or none at 2 h postdose)
are not always relevant in primary care, where patient
experiences and preferences are of greater importance for
the evaluation of treatment satisfaction and success. Indeed,
the IHS guidelines for migraine treatment trials state that
patients’ evaluation of migraine medications is a clinically
relevant measure (12). In contrast to the majority of clinical
trials performed to date, an open-label study design in a
real-life primary care setting, without a dictated dosing regi-
men (although still following the prescribing information),
is more relevant to PCPs as the results are more likely to
reﬂect the situation in clinical practice.
The ‘Zomig Appropriate for Primary care’ (ZAP) pro-
gramme was designed to address the needs of PCPs with
the aim of improving the diagnosis and management of
migraine patients in primary care (13). As part of this ini-
tiative, a clinical programme was developed in which zolmi-
triptan was used as a ﬁrst-line treatment to give
participating PCPs hands-on experience of using triptan
therapy to manage patients with migraine. In turn, treat-
ment outcomes were generated that were meaningful to
both patients and physicians. This programme encompassed
three clinical studies that were performed in the primary
care setting: an international core study (Canada, France
and the UK) and two local studies (USA and Spain). The
present manuscript reports the results of the international
core study that utilised zolmitriptan orally disintegrating
tablet (ODT) 2.5 mg, which has been shown to be an
effective and well-tolerated acute treatment for migraine in
controlled clinical trials (14–16). The objectives of the core
study were to: (i) create a real-life primary care situation by
giving patients options in the management of individual
migraine attacks; i.e. patient-centred stratiﬁed care; and (ii)
generate patient-reported outcomes relevant to PCPs by
focussing on patients’ experiences regarding the efﬁcacy and
tolerability of zolmitriptan ODT. Patient preferences and
treatment satisfaction were also assessed.
STUDY METHODS
Study Population
To reﬂect a real-life situation, the inclusion/exclusion cri-
teria for the study were as stated in the prescribing informa-
tion for zolmitriptan ODT. Patients (aged: 18–65 years)
presenting in primary care with an established diagnosis of
migraine with or without aura, who had experienced at least
one migraine attack per month in the previous 3 months,
were eligible for inclusion. Exclusion criteria included: a his-
tory of basilar, ophthalmoplegic or hemiplegic migraine or
any potentially serious neurological condition that is associ-
ated with headache; a history of, or signiﬁcant risk factors
for, cardiovascular disease; uncontrolled hypertension; and
use of monoamine oxidase-A inhibitors, methysergide or
methylergonovine in the 2 weeks before entering the study.
Study Design
This multinational, multicentre, 6-month, open-label study
was conducted at 79 study centres between October 2003
and December 2004. The study was conducted in accord-
ance with the Declaration of Helsinki and all investigators
complied with Good Clinical Practice. Written informed
consent was obtained from each patient prior to participa-
tion in the study, the protocol having received independent
institutional review board or ethical committee approval
from the respective participating centres.
Patients’ eligibility for inclusion in the study was deter-
mined at an initial screening visit. Migraine headache his-
tory and usual migraine treatments (if any) were recorded.
Patients were instructed to treat up to three migraine attacks
per month with zolmitriptan ODT 2.5 mg. All other
migraine attacks occurring during the study period were
treated with the patients’ usual migraine medication (inclu-
ding other triptans). Patients could treat at any time after
the onset of headache pain and for any symptom severity
(again reﬂecting a real-life situation). After taking zolmitrip-
tan ODT, patients could not use a second dose of zolmi-
triptan or other escape medication for at least 2 h.
Investigator-led questionnaires were used to record
patient treatment experiences and preferences at 2 and
6 months after the start of the study. Information regarding
adverse events was recorded. At the end of the study, the
PCP also completed a short questionnaire, indicating whe-
ther or not the prescription of zolmitriptan ODT should be
continued for each patient in the future.
Assessments
The primary outcome variable was the proportion of
patients who wanted to continue to use zolmitriptan ODT
after 6 months’ treatment. Secondary outcome variables
from the patient questionnaire included:
• the reasons why patients wanted/did not want to con-
tinue using zolmitriptan ODT;
• the proportion of patients who reported zolmitriptan
ODT to be convenient to use (agree/disagree);
• the proportion of patients who reported that zolmitrip-
tan ODT allows early treatment of a migraine attack
(agree/disagree);
• patient’s assessment of:
• efﬁcacy [how long before zolmitriptan ODT starts to
work; the time to headache disappearing; the propor-
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rapidly effective and highly effective (agree/disagree)];
• reliability [the proportion of patients who reported
zolmitriptan ODT to be a reliable treatment (agree/
disagree)];
• value [the time to return to usual activities; satisfac-
tion with zolmitriptan ODT (rated on a four-point
scale: very satisﬁed, satisﬁed, unsatisﬁed and very
unsatisﬁed); the proportion of patients who prefer
zolmitriptan ODT to usual therapy (agree/disagree)];
• control [the proportion of patients reporting to be
conﬁdent in quick control of migraine with zolmi-
triptan ODT; the proportion of patients who repor-
ted being back in control of life with zolmitriptan
ODT (agree/disagree)];
• tolerability [the proportion of patients who reported
that side effects were of little/no concern (agree/dis-
agree/had no side effects); the proportion of patients
who reported that side effects would stop use of zo-
lmitriptan ODT again].
Secondary outcome variables from the PCP questionnaire
were the proportion of patients for whom PCPs wanted to
continue prescribing zolmitriptan ODT and the reasons
why PCPs wanted/did not want to continue prescribing
such therapy.
Statistical Analysis
The primary outcome variable was the proportion of
patients wanting to continue using zolmitriptan ODT. A
sample size of 600 patients was estimated based on the least
favourable scenario, where an equal number of patients
wanted to continue/discontinue the use of zolmitriptan
ODT. It was considered that the sample size, even in the
least favourable scenario, would be large enough to produce
clinically relevant ﬁndings representative of the general
migraine population. All outcome variables were summa-
rised descriptively and no hypothesis test was performed.
All patients treating at least one migraine attack with
study medication were included in the safety population.
The intention-to-treat (ITT) population comprised all
patients who treated at least one migraine attack with study
medication and who returned to the clinic to provide post-
treatment assessment data.
STUDY RESULTS
Study Population
A total of 621 patients were enrolled in the study, of whom
597 patients treated at least one migraine attack with study
medication and were included in the safety population. The
ITT population comprised 595 patients (Canada: 190;
France: 204; and UK: 201), who treated a total of 7171
migraine attacks with zolmitriptan ODT and provided post-
treatment efﬁcacy data. Demographic and baseline clinical
characteristics of the ITT population are shown in Table 1.
The ITT population was predominantly female (508;
85.4%), with a mean age of 41.8 years. The mean age at
migraine onset was 22.8 years, and the mean number of
migraine attacks experienced in the 3 months before the
study was 8.5. Migraine attacks were generally associated
with photophobia (87.4% of patients) and nausea (83.7%).
The most frequently used migraine treatments were analge-
sics (84.6% of patients), triptans (71.1%) and NSAIDs
(64.7%). Level of satisfaction with usual migraine therapy
(satisﬁed or very satisﬁed) ranged from 20.6% for ergots to
85.7% for triptans (Table 1).
A total of 97 out of 621 enrolled patients (15.6%) did
not complete the 6-month study period, most commonly
because of the lack of efﬁcacy (24; 3.9%), adverse events
(21; 3.4%) and the loss to follow up (19; 3.1%). In accord-
ance with the study design, these patients were expected to
continue with their usual antimigraine therapy.
Assessments
Of the 504 patients who completed the 6-month question-
naire, three quarters (380; 75.4%) wished to continue using
Table 1 Demographic and baseline clinical characteristics of the
intention-to-treat population (n ¼ 595)
Characteristic
Mean age (years) 41.8
Gender; n (%)
Male 87 (14.6)
Female 508 (85.4)
Mean age at onset of migraine attacks (years) 22.8
Mean number of migraine attacks
in the last 3 months
8.5
Migraine-associated symptoms; n (%)
Photophobia 520 (87.4)
Nausea 498 (83.7)
Phonophobia 438 (73.6)
Vomiting 196 (32.9)
Usual migraine medication; n (%)
Analgesics (other than NSAIDs) 501 (84.6)
Triptans 421 (71.1)
NSAIDs 383 (64.7)
Antiemetics 181 (30.6)
Ergots 102 (17.2)
Patient satisfaction* with usual migraine medication; n (%)
Triptans 361/421 (85.7)
Antiemetics 75/181 (41.4)
NSAIDs 135/383 (35.2)
Analgesics (other than NSAIDs) 167/501 (33.3)
Ergots 21/102 (20.6)
*Satisﬁed or very satisﬁed. NSAIDs, non-steroidal anti-inﬂammatory drugs.
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to continue using zolmitriptan ODT included effectiveness
[93.2% (of 380)], ease of use (80.8%) and rapid effect
(78.4%) (Figure 1). Of the 124 (24.6%) patients who did
not want to continue using zolmitriptan ODT, reasons why
included preferred usual treatment [66.9% (of 124)], poor
effect (53.2%) and adverse events (22.6%). Almost all
(95.4%) of the patients completing the 6-month question-
naire agreed that zolmitriptan ODT was convenient to use
and 84.3% of patients reported that zolmitriptan ODT
allowed early treatment.
Over half (56.6%) of the patients reported that zolmitrip-
tan ODT typically starts to work within 30 min of adminis-
tration (Figure 2). Furthermore, the cumulative percentage
of patients reporting that zolmitriptan ODT starts to work
within 2 h postdose was 90.8%. When asked how long it
takes for headache pain to disappear after taking zolmitrip-
tan ODT, approaching two-thirds (60.9%) of patients sta-
ted within 60 min and 80.4% stated within 2 h (Figure 3).
Zolmitriptan ODT was considered to be rapidly and
highly effective by 79.3% and 76.3% of patients, respect-
ively. In addition, 58.5% would choose zolmitriptan ODT
to treat migraine attacks of any intensity and 83.7% stated
that zolmitriptan ODT was a reliable treatment.
When asked about the value of zolmitriptan ODT,
74.3% of patients were able to resume usual activities within
2 h of treatment (Figure 4). Most patients (84.1%) were
satisﬁed/very satisﬁed with zolmitriptan ODT; only 5.0% of
patients were very unsatisﬁed with treatment (Figure 5).
Over two-thirds of patients (70.9%) preferred zolmitriptan
ODT to their usual migraine therapies. In the subgroup of
358 patients who had been using other triptans, the results
1.8
31.6
47.4
61.8
65.3
66.3
78.4
80.8
93.2
02 0 4 0 6 0 8 0 1 0 0
Other
Good for nausea
Only one dose needed
Fast return to normal function
Side effects of no concern
Allows early treatment
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Figure 1 Reasons stated by migraineurs
for wanting to continue using
zolmitriptan orally disintegrating tablet
after 6 months’ treatment (patients could
give more than one reason; n ¼ 380)
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Figure 2 Cumulative percentage of migraineurs who reported
that zolmitriptan orally disintegrating tablet starts to work within
15, 30, 60, 120 and 240 min of administration [n ¼ 595 (missing
data: n ¼ 93)]
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Figure 3 Cumulative percentage of migraineurs who reported
that headache pain had disappeared within 15, 30, 60, 120 and
240 min of administration of zolmitriptan orally disintegrating
tablet [n ¼ 595 (missing data: n ¼ 94)]
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treatment. The majority of patients (77.7%) felt conﬁdent
that migraine could be quickly controlled using zolmitriptan
ODT, with 56.4% agreeing that treatment with zolmitriptan
ODT resulted in being back in control of life.
After 6 months’ treatment experience, 90.4% of patients
reported either no zolmitriptan ODT-related adverse events
(50.6%) or stated that adverse events were of little or no
concern (39.8%). Only 6.4% of patients stated that adverse
events would prevent future use of zolmitriptan ODT.
Primary care physicians wished to continue prescribing
zolmitriptan ODT for over two-thirds of 585 evaluable
patients (396; 67.7%). Reasons why included effectiveness
[94.7% (of 396)], rapid effect (74.0%) and ease of use
(73.7%). Of the PCPs who did not wish to continue
prescribing zolmitriptan ODT for 189 (32.3%) patients,
reasons why included poor effect [52.4% (of 189)] and pre-
ferred usual treatment (48.7%).
DISCUSSION
Migraine is highly prevalent in primary care. However,
there is little support for PCPs to manage this condition,
resulting in under-diagnosis and under-treatment of
patients. Consequently, when asked about what additional
information would inﬂuence the wider use of migraine-spe-
ciﬁc medications in primary care, many PCPs stated efﬁc-
acy, tolerability and cost-effectiveness information (data on
ﬁle, AstraZeneca). All of these issues are addressed in the
present study, which was conducted as part of the wider
ZAP programme.
Efﬁcacy is generally seen as the most important factor in
determining migraine treatment selection. However, tradi-
tional measures of efﬁcacy are not relevant to most PCPs,
for whom patient-related efﬁcacy end-points are more
meaningful. The current study was therefore designed to
allow physicians to receive feedback from patients and to
make their own assessment on treatment in terms that are
more meaningful to them.
The efﬁcacy of zolmitriptan ODT was highly acceptable
to patients for the acute treatment of migraine, as indicated
by the high proportion of patients who wished to continue
to use it. Most patients were satisﬁed or very satisﬁed with
zolmitriptan ODT and preferred it to their usual therapy
(including other triptans). The fact that many patients pre-
ferred zolmitriptan ODT to their usual triptan therapy is
notable, as the level of satisfaction with such treatment was
particularly high (85.7%). Furthermore, PCPs wished to
continue prescribing zolmitriptan ODT for over two-thirds
of patients. This provides a good indication that the combi-
nation of hands-on experience of using zolmitriptan ODT,
the more patient-orientated end-points and patient feedback
on treatment experience and preferences, were motivating
and relevant to PCPs. Furthermore, the positive responses
from patients and physicians to the efﬁcacy variables used
in this study, and the fact that they were highly consistent
across countries (data not shown), makes these variables use-
ful for future studies.
Primary care physicians frequently cite concerns about
safety and tolerability of the triptans as a barrier to use. The
ZAP core study results indicate very strongly that this per-
ception is misplaced, as nine out of 10 patients reported no
adverse events or events that were of little or no concern.
These results supplement the regulatory clinical trial data
which demonstrate that zolmitriptan ODT is a well-toler-
ated treatment for migraine (14,15). The withdrawal rate
because of adverse events in this study was very low (3.4%)
and similar to that seen in controlled studies of zolmitriptan
ODT (14,16).
3.4
20.1
55.3
74.3
85.0
0
20
40
60
80
100
P
a
t
i
e
n
t
s
 
(
%
)
≤15 ≤30 ≤60 ≤120 ≤240
Time postdose (minutes)
Figure 4 Cumulative percentage of migraineurs who reported the
ability to resume usual activities within 15, 30, 60, 120 and
240 min of administration of zolmitriptan orally disintegrating
tablet [n ¼ 595 (missing data: n ¼ 94)]
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Figure 5 The percentage of migraineurs who were very satisﬁed,
satisﬁed, unsatisﬁed or very unsatisﬁed with zolmitriptan orally
disintegrating tablet after 6 months’ treatment [n ¼ 595 (missing
data: n ¼ 92)]
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in the current study (it was not a health economics
study), the value of triptan therapy to patients was
clearly expressed in terms of both having a rapid return
to usual daily activities and being back in control of life
quickly, thus reducing the negative impact of a migraine
attack.
A limitation of the present study is that it utilised an
open-label, non-comparative design. Consequently, the
results may have been confounded by the psychological
impact of patients’ willingness to please their physician,
although the results parallel the efﬁcacy and favourable tol-
erability of zolmitriptan ODT in controlled clinical trials
(14–16). The lack of a comparative arm also means that
patient preference for zolmitriptan ODT may reﬂect a pref-
erence for the drug itself, rather than this speciﬁc formula-
tion. These limitations, however, need to be set against the
fact that the study was conducted under conditions that
mirrored real life as closely as possible, and thereby provi-
ded treatment experience data that was meaningful to both
patients and physicians.
CONCLUSIONS
Hands-on clinical experience with zolmitriptan ODT, as
part of the wider ZAP programme that encompasses physi-
cian education, simpliﬁed guidelines and diagnostic and
treatment tools, was associated with high rates of patient
and physician satisfaction in the management of migraine in
primary care.
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